Please login or sign up to post and edit reviews.
E135 - (CME) The Art of Switching Antipsychotics to Better Treat Patients with Schizophrenia
Podcast |
NEI Podcast
Media Type |
audio
Categories Via RSS |
Education
Health & Fitness
Medicine
Publication Date |
Jan 26, 2022
Episode Duration |
00:56:15

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl on best practices for switching antipsychotics.

Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-Switch

Learning Objectives: After completing this educational activity, you should be better able to:

  • Understand the relevance of receptor binding properties and pharmacokinetic profiles when switching antipsychotics
  • Follow evidence-based guidelines when switching antipsychotics

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. 

Credit Types. The following are being offered for this activity:

  • Nurse Practitioner (ANCC): contact hours
  • Pharmacy (ACPE): knowledge-based contact hours  
  • Physician (ACCME): AMA PRA Category 1 Credits
  • Physician Assistant (AAPA): Category 1 CME credits
  • Psychology (APA): CE credits
  • Social Work (ASWB-ACE): ACE CE credits
  • Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships, which were then mitigated prior to the activity being presented.

Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

Interviewee

Stephen M. Stahl, MD, PhD, DSc (Hon.) 

Clinical Professor, Department of Psychiatry and Neuroscience, University of California, Riverside School of Medicine, Riverside, CA

Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA

Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK

Director of Psychopharmacology Services, California Department of State Hospitals, Sacramento, CA

Grant/Research: Acadia, Avanir, Braeburn, Intra-Cellular, Ironshore, Lilly, Neurocrine, Otsuka, Shire, Sunovion

Consultant/Advisor: AbbVie, Acadia, Alkermes, Allergan, Arbor, Axovant, Axsome, Celgene, ClearView, Concert, EMD Serono, Eisai, Ferring, Impel, Intra-Cellular, Ironshore, Janssen, Karuna, Lilly, Lundbeck, Merck, Otsuka, Pfizer, Relmada, Sage, Servier, Shire, Sunovion, Takeda, Taliaz, Teva, Tonix, Tris, Vifor

Speakers Bureau: Acadia, Lundbeck, Otsuka, Perrigo, Servier, Sunovion, Takeda, Teva, Vertex

Board Member: Genomind

Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and implicit bias can be found in this downloadable handout.

Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies.

Released: January 26, 2022          CE credit expires: January 26, 2025

 

 

 

 

 

This episode currently has no reviews.

Submit Review
This episode could use a review!

This episode could use a review! Have anything to say about it? Share your thoughts using the button below.

Submit Review